SCHEMBL3908236

SCHEMBL3908236

O=C(O)CN1C(=O)/C(=C/c2ccc(I)o2)SC1=S

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ KDM4E B2RXH2 2/20 0.69
▸ MEN1 O00255 2/20 0.69
▸ POLB P06746 2/20 0.69
▸ TDP1 Q9NUW8 2/20 0.69
▸ L3MBTL1 Q9Y468 2/20 0.69
▸ MAP3K5 Q99683 2/20 0.66
▸ USP2 O75604 1/20 0.66
▸ ALDH1A1 P00352 1/20 0.66
▸ LMNA P02545 1/20 0.66
▸ RECQL P46063 1/20 0.66
▸ SAE1 Q9UBE0 1/20 0.66
▸ UBA2 Q9UBT2 1/20 0.66
▸ APEX1 P27695 1/20 0.64
▸ PTPN22 Q9Y2R2 2/20 0.62
▸ PTPN12 Q05209 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3908238 1.00 MAPT (0.69) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL3907479 0.88 MAPT (0.66) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL3907475 0.88 MAPT (0.66) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL10492310 0.86 MAPT (0.66) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL29754022 0.86 MAPT (0.66) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL10492308 0.86 MAPT (0.66) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL3893475 0.85 PTPN22 (0.72) MAPTKMT2AMEN1TDP1MAP3K5
SCHEMBL3893480 0.85 PTPN22 (0.72) MAPTKMT2AMEN1TDP1MAP3K5
SCHEMBL13056366 0.84 MAPT (0.79) MAPTKMT2AKDM4EMEN1POLB
SCHEMBL10492189 0.83 MAPT (0.61) MAPTKMT2AKDM4EMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO claimed
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 — — US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 MAPT 1762/4885KMT2A 3471/4885KDM4E 3258/4885
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MAPT 1187/4885KMT2A 901/4885KDM4E 1357/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA MAPT 1460/4885KMT2A 2501/4885KDM4E 2184/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MAPT 880/4885KMT2A 1020/4885KDM4E 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback